Sezary Syndrome
Symptoms, Doctors, Treatments, Advances & More

Learn About Sezary Syndrome

What is the definition of Sezary Syndrome?

Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform.

What are the causes of Sezary Syndrome?

The cause of Sézary syndrome is unknown. Most affected individuals have one or more chromosomal abnormalities, such as the loss or gain of genetic material. These abnormalities occur during a person's lifetime and are found only in the DNA of cancerous cells. Abnormalities have been found on most chromosomes, but some regions are more commonly affected than others. People with this condition tend to have losses of DNA from regions of chromosomes 10 and 17 or additions of DNA to regions of chromosomes 8 and 17. It is unclear whether these alterations play a role in Sézary syndrome, although the tendency to acquire chromosomal abnormalities (chromosomal instability) is a feature of many cancers. It can lead to genetic changes that allow cells to grow and divide uncontrollably.

How prevalent is Sezary Syndrome?

Sézary syndrome is a rare condition, although its prevalence is unknown. It is the second most common form of cutaneous T-cell lymphoma after mycosis fungoides, accounting for approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma.

Is Sezary Syndrome an inherited disorder?

The inheritance pattern of Sézary syndrome has not been determined. This condition occurs in people with no history of the disorder in their family and is not thought to be inherited in most cases.

Who are the top Sezary Syndrome Local Doctors?
Larisa Geskin
Elite in Sezary Syndrome
Elite in Sezary Syndrome

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Larisa Geskin is an Oncologist in New York, New York. Dr. Geskin is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.

Christiane Querfeld
Elite in Sezary Syndrome
Elite in Sezary Syndrome

Christiane Querfeld, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
Languages Spoken:
English

Christiane Querfeld is a Dermatologist in Duarte, California. Dr. Querfeld is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Alain H. Rook
Elite in Sezary Syndrome
Dermatology
Elite in Sezary Syndrome
Dermatology

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients

Alain Rook is a Dermatologist in Philadelphia, Pennsylvania. Dr. Rook is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome. Dr. Rook is currently accepting new patients.

What are the latest Sezary Syndrome Clinical Trials?
A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Summary: This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Open Label, Single-cohort, and Multi-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients With Sézary Syndrome at Single-cell Resolution

Summary: The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and ...

Who are the sources who wrote this article ?

Published Date: May 17, 2021
Published By: National Institutes of Health